Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
Total Valuation
AbCellera Biologics has a market cap or net worth of $646.63M. The enterprise value is $279.22M.
Market Cap$646.63M
Enterprise Value$279.22M
Share Statistics
AbCellera Biologics has 297.99M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding297.99M
Owened by Insiders43.24%
Owened by Instutions24.53%
Financial Efficiency
AbCellera Biologics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -19.92%.
Return on Equity (ROE)-15.42%
Return on Assets (ROA)-11.97%
Return on Invested Capital (ROIC)-19.92%
Return on Capital Employed (ROCE)-24.52%
Revenue Per Employee$48,379.195
Profits Per Employee-$273,250
Employee Count596
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of AbCellera Biologics is -5.30. AbCellera Biologics’s PEG ratio is -0.68.
PE Ratio-5.30
PS Ratio29.91
PB Ratio0.82
Price to Fair Value0.82
Price to FCF-4.61
Price to Operating Cash Flow-7.94
PEG Ratio-0.68
Income Statement
In the last 12 months, AbCellera Biologics had revenue of $28.83M and earned -$162.86M in profits. Earnings per share was -$0.56.
Revenue$28.83M
Gross Profit-$54.26M
Operating Income-$314.77M
Pretax Income-$200.40M
Net Income-$162.86M
EBITDA-212.25M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was -$108.05M and capital expenditures -$78.08M, giving a free cash flow of -$186.13M billion.
Operating Cash Flow-$108.05M
Free Cash Flow-$186.13M
Free Cash Flow per Share-$0.62
Dividends & Yields
AbCellera Biologics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-21.68%
Earnings Yield-18.88%
Stock Price Statistics
Beta1.50
52-Week Price Change-52.74%
50-Day Moving Average2.64
200-Day Moving Average2.78
Relative Strength Index (RSI)32.69
Average Volume (3m)4.28M
Important Dates
AbCellera Biologics upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
AbCellera Biologics as a current ratio of 9.81, with Debt / Equity ratio of 0.06
Current Ratio9.81
Quick Ratio9.81
Debt to Market Cap0.07
Net Debt to EBITDA0.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, AbCellera Biologics has paid -$37.54M in taxes.
Income Tax-$37.54M
Effective Tax Rate18.73%
Enterprise Valuation
AbCellera Biologics EV to EBITDA ratio is -3.76, with an EV/FCF ratio of -4.10.
EV to Sales26.59
EV to EBITDA-3.76
EV to Free Cash Flow-4.10
EV to Operating Cash Flow-7.06
Balance Sheet
AbCellera Biologics has $625.61M in cash and marketable securities with $60.74M in debt, giving a net cash position of -$564.87M billion.
Cash & Marketable Securities$625.61M
Total Debt$60.74M
Net Cash-$564.87M
Net Cash Per Share-$1.90
Tangible Book Value Per Share$3.28
Margins
Gross margin is 100.00%, with operating margin of -1091.69%, and net profit margin of -564.83%.
Gross Margin100.00%
Operating Margin-1091.69%
Pretax Margin-695.02%
Net Profit Margin-564.83%
EBITDA Margin-708.04%
EBIT Margin-1044.45%
Analyst Forecast
The average price target for AbCellera Biologics is $13.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.50
Price Target Upside522.12%
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-24.17%
EPS Growth Forecast-9.24%